儿童耐药结核病中利奈唑胺药代动力学与贫血的建模研究
该研究在南非和印度纳入112名儿童,验证了利奈唑胺群体药代动力学模型,并分析基线血红蛋白和利奈唑胺药时曲线下面积与3级或4级贫血的关系,结果支持当前推荐的儿童利奈唑胺剂量10-15 mg/kg。
要点
- 基线血红蛋白每降低1 g/dL,发生3级或4级贫血的比值比为2.64(95%CI 1.98-3.62)。
- 利奈唑胺药时曲线下面积每增加1 mg/L×h,3级或4级贫血的比值比为1.012(95%CI 1.007-1.017)。
- 研究数据证实了当前推荐的儿童利奈唑胺剂量10-15 mg/kg。
核心结论
- 数据证实了当前推荐的儿童利奈唑胺剂量。
- 儿童贫血风险应仔细考虑并监测,基线血红蛋白低的儿童起始利奈唑胺会增加发生3级或4级贫血的概率。
研究设计与样本
- 前瞻性纳入队列研究,纳入112名儿童,中位年龄7.2岁(四分位距2.2-16.3),来自南非(n=87)和印度(n=25)。
- 其中24名儿童提供了新的利奈唑胺药代动力学数据,用于验证已有的群体药代动力学模型。
- 使用非线性混合效应模型验证模型,并构建多变量有序逻辑回归模型预测贫血发生率。
主要发现
- 基线血红蛋白每降低1 g/dL,发生3级或4级贫血的比值比为2.64(95%CI 1.98-3.62)。
- 利奈唑胺药时曲线下面积每增加1 mg/L×h,发生3级或4级贫血的比值比为1.012(95%CI 1.007-1.017)。
- 当前推荐的儿童利奈唑胺剂量10-15 mg/kg的群体药代动力学模型得到新数据验证。
关键数值与推荐
- 当前推荐的儿童利奈唑胺剂量为10-15 mg/kg,该模型得到验证。
临床怎么用
- 作者认为,儿童贫血风险应仔细考虑并监测。
- 作者指出,基线血红蛋白低的儿童起始利奈唑胺会增加发生3级或4级贫血的概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment, is associated with treatment-limiting toxicities, including anemia. Patient-level and linezolid pharmacokinetic risk factors for anemia have not been well described in children treated for RR/MDR-TB. METHODS: We evaluated the pharmacokinetics of linezolid and longitudinal hemoglobin data to validate an existing population linezolid pharmacokinetic model. We assessed the impact of linezolid pharmacokinetics and the risk of developing anemia in a prospectively enrolled cohort of children. A previously published population pharmacokinetic linezolid model was validated using nonlinear mixed effects modeling. A multivariable ordinal logistic regression model was built to predict the incidence of anemia. RESULTS: A total of 112 children, median age 7.2 years (interquartile range, 2.2-16.3), were included from South Africa (n = 87) and India (n = 25). Of these, 24 children contributed new linezolid pharmacokinetic data. The population pharmacokinetic model, which informs the currently recommended linezolid dosing in children (10-15 mg/kg), was validated with these additional new data. For every 1 g/dL lower baseline hemoglobin level, the odds of developing grade 3 or 4 anemia increased by 2.64 (95% confidence interval [CI], 1.98-3.62). For every 1 mg/L × h higher linezolid area under the concentration-time curve, the odds of developing grade 3 or 4 anemia increased by 1.012 (95% CI, 1.007-1.017). CONCLUSIONS: Taken together, these data confirm currently recommended linezolid doses for children. The risk of anemia in children should be carefully considered and monitored. Initiating linezolid in children with low baseline hemoglobin increases the probability of experiencing grade 3 or 4 anemia.
引用
- Brooks JT, Solans BP, Béranger A, et al. Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis. Clin Infect Dis. 2024. PMID: 39422476. doi:10.1093/cid/ciae497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。